Navigation Links
Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
Date:7/13/2011

STEVENSVILLE, Md., July 13, 2011 /PRNewswire-USNewswire/ -- Vapotherm, a privately held manufacturer of respiratory care devices for hospital and home use, announced today that it has received approval from the Medical Device Bureau of Health Canada for the Precision Flow® Heliox device which will be launched later this year in the Canadian hospital market. The device is part of Vapotherm's High Flow Specialty Gas Program.

"We are pleased to receive our license in Canada for Precision Flow® Heliox, the first high flow device specifically designed for heliox delivery, said Bill Niland, Chairman and Director of New Business Development at Vapotherm."  The Company has also submitted for 510(k) clearance of the device in the U.S. and is also submitting for CE marking for other international markets.  

Vapotherm's High Flow Specialty Gas Program was created to expand High Flow Therapy (HFT) beyond air and oxygen to other medical and specialty gases.  The Company's flagship platform device, the Precision Flow®, was developed with a modular design concept to allow for several specialty applications in neonatal, pediatric and adult patient populations.  In all applications, the device optimizes the delivery of gases via precise blending, flow control and temperature management.  As with all Vapotherm HFT products, the overall goal is non-invasive respiratory support via a simple nasal cannula in a device that is easy for clinicians to operate but comprehensive in terms of safety and performance features. The Company plans to announce additional modules in the coming weeks.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit www.vtherm.com.

Contact: Kevin Thibodeau, Executive Vice President of Sales and Marketing
410-604-3977


'/>"/>
SOURCE Vapotherm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vapotherm, Inc. Announces CE Mark Approval for Flowrest® Homecare Device
2. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
3. Vapotherm Announces New Exclusive Distribution Agreement with Hippo Medical for South Korea
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):